title: Dissolution and pharmacokinetics of a novel micronized aspirin formulation.
abstract: Aspirin (acetylsalicylic acid, ASA) has been used as an analgesic, antipyretic and antiinflammatory drug for many years. A new 500 mg aspirin tablet formulation containing micronized active ingredient and an effervescent component has been developed for potential improvement in the onset of action for acute pain treatment. This paper describes the dissolution and the pharmacokinetics of the new formulation in comparison with regular aspirin tablets, aspirin granules and aspirin effervescent tablets. Micronized aspirin tablets dissolve significantly faster over a pH range from 1.2 to 6.8 compared to regular 500 mg aspirin tablets. Plasma concentration time curve comparison to regular 500 mg aspirin tablets showed a substantial improvement in the time to maximum plasma concentrations (T(max)) (ASA 17.5 min vs. 45 min) and an increase in maximum plasma concentration (C(max)) (ASA 13.8 μg/ml vs. 4.4 μg/ml) while the overall extent of exposure (AUC) remains almost unchanged. The data suggest a potential improvement for onset of action in treating acute pain with the new micronized aspirin formulation.
authors: Bayer Consumer Care, Morristown, NJ, USA. michael.voelker@bayer.com
authors: M
authors: M
authors: Voelker
authors: M
authors: M
authors: Hammer
mesh_terms: D000328:Adult; D001241:Aspirin / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D002626:Chemistry, Pharmaceutical; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D008297:Male; D020156:Salicylic Acid / Q000493:pharmacokinetics; D012995:Solubility; D013607:Tablets
chemical_list: D013607:Tablets; D020156:Salicylic Acid; D001241:Aspirin